Communiqués Orion Oyj

Actions

ORNBV

FI0009014377

Produits pharmaceutiques

PEA

Temps réel estimé Tradegate 17:25:01 08/10/2026			Varia. 5j.	Varia. 1 janv.
80,85 ^EUR	-2,59 %		-0,12 %	+26,94 %

06/10	Orion Corporation et Qilu Pharma Europe annoncent un accord concernant un biosimilaire du pembrolizumab destiné au marché européen	CI
06/10	Orion va commercialiser en Europe le biosimilaire du pembrolizumab de Qilu Pharma	MT

Communiqués

07/10	125,000 Orion Corporation A shares converted into B shares	GL
07/10	125,000 Orion Corporation A shares converted into B shares	AQ
06/10	Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company's first biologic candidate to reach clinical testing	AQ
06/10	Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market	GL
05/10	Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing	GL
30/09	Orion Corporation completed share acquisitions	GL
30/09	Orion Corporation: Acquisition of own shares during week 40, 2026	GL
25/09	Orion Corporation: Acquisition of own shares during week 39, 2026	GL
18/09	Orion Corporation: Acquisition of own shares during week 38, 2026	GL
11/09	Orion Corporation: Acquisition of own shares during week 37, 2026	GL
04/09	Orion Corporation: Acquisition of own shares during week 36, 2026	GL
04/09	102,000 Orion Corporation A shares converted into B shares	GL
27/08	Orion Corporation to commence acquisition of own shares for its share-based incentive plans	GL
10/08	Orion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint	GL
17/07	Orion Oyj : Half-Year Financial Report 2026	PU
17/07	Orion Group Half-Year Financial Report January–June 2026	GL
17/07	Orion Corporation’s financial reporting and Annual General Meeting in 2027	GL
15/07	45,611 Orion Corporation A shares converted into B shares	GL
06/07	Orion publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026	AQ
03/07	Orion Oyj : publishes Half-Year Report for January-June 2026 and holds a webcast on 17 July 2026	PU
03/07	Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026	GL
30/06	Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market	GL
23/06	Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission	GL
18/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL
17/06	Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)	GL